ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Silencing of MAT2A inhibits gastric cancer cell proliferation, migration, and invasion through activation of the p53 pathway.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThis study aimed to evaluate the effects of MAT2A silencing on the proliferation, migration, and invasion of gastric cancer (GC) cells and to investigate the underlying molecular mechanisms.
methodsMAT2A expression in GC tissues and adjacent normal tissues was assessed using immunohistochemistry and western blotting. Two GC cell lines with elevated MAT2A expression underwent gene silencing. Cellular proliferation, migration, and invasion were evaluated using EdU incorporation, Transwell, wound healing, and flow cytometry assays. Transcriptomic profiling was conducted to identify downstream pathways affected by MAT2A silencing, demonstrating significant enrichment of the p53 signaling pathway. To further clarify this mechanism, the p53 pathway was inhibited in MAT2A-silenced cells, and changes in p53 and p21 protein expression, along with alterations in proliferation, migration, and invasion, were reassessed.
resultsMAT2A expression was significantly higher in GC tissues and cell lines compared with adjacent normal controls. Silencing of MAT2A induced cell cycle arrest, suppressed proliferation and metastatic capacity, and enhanced apoptosis, accompanied by an increased expression of p53 and p21 proteins. Inhibition of p53 with PFT-α reduced both p53 and p21 levels and reversed the suppressive effects of MAT2A silencing on GC cell proliferation, migration, and invasion.
conclusionMAT2A silencing induces cell cycle arrest, enhances apoptosis, and inhibits malignant phenotypes of GC cells, including proliferation, migration, and invasion, through activation of the p53 signaling pathway.
Indexed as
Identifiers
41419675What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.